Skip to main content

Posts

Showing posts from November 19, 2024

The Bankruptcy of Spirit Airlines and the Resilience of Pharmaceuticals: A Personal Reflection

The recent bankruptcy of Spirit Airlines has triggered widespread concern, forcing many investors to reevaluate their perspectives on risk within the airline sector. Airlines, by nature, have always struck me as inherently risky due to their sensitivity to economic cycles, fuel costs, and operational complexities. However, I once viewed discount airlines like Spirit as somewhat more resilient because of their leaner operational models and focus on cost-conscious travelers. I recall considering Spirit Airlines as a potential investment when my daughter was four or five years old, shortly after her first magical trip to Disney. The airline’s no-frills approach seemed appealing, especially as budget-conscious families frequently turned to it for affordable travel. Yet, as much as I admired the company’s growth strategy at the time, I ultimately hesitated, wary of the long-term uncertainties tied to the industry.